Floatz logo

Serplulimab

PD-1 Inhibitor

Fujian Cancer Hospitalmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

15 Active assets in the PD-1 Inhibitor cohort.

Asset / SponsorPhaseRating
Regorafenib
Peking Union Medical College Hospital
Phase 2CCC
Eloxatin
Zhejiang Provincial People's Hospital
Phase 1/2CC
CIS-DIAMMINEDICHLOROPLATINUM II
Guangzhou Medical University
Phase 1/2CC
Iparomlimab
Guangzhou Medical University
Phase 1/2CC
Carboplatin
Guangzhou Medical University
Phase 1/2CC

View all 15 →

Same molecule, other indications

Serplulimab is also rated in:

ImmunotherapyDormant
BB
Indicative ·
70 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →